Abstract
A growing wealth of evidence indicates that the key pathological event in Alzheimers disease is the conversion of the normal soluble amyloid-β peptide into β-sheet-rich oligomeric structures which have a neurotoxic activity and ability to form insoluble amyloid deposits that accumulate in the brain. b-sheet breakers constitute a new class of drugs that are designed to specifically bind amyloid-β peptide and block and / or reverse this abnormal conformational change. In this article we review this approach, describe diverse compounds reported to have this activity and summarize the data supporting the view that b-sheet breakers could be serious candidates to combat this devastating disease.
Keywords: alzheimer disease, amyloid, therapy
Current Drug Targets
Title: β-Sheet Breakers for Alzheimers Disease Therapy
Volume: 5 Issue: 6
Author(s): Bieler S. and Soto C.
Affiliation:
Keywords: alzheimer disease, amyloid, therapy
Abstract: A growing wealth of evidence indicates that the key pathological event in Alzheimers disease is the conversion of the normal soluble amyloid-β peptide into β-sheet-rich oligomeric structures which have a neurotoxic activity and ability to form insoluble amyloid deposits that accumulate in the brain. b-sheet breakers constitute a new class of drugs that are designed to specifically bind amyloid-β peptide and block and / or reverse this abnormal conformational change. In this article we review this approach, describe diverse compounds reported to have this activity and summarize the data supporting the view that b-sheet breakers could be serious candidates to combat this devastating disease.
Export Options
About this article
Cite this article as:
S. Bieler and C. Soto, β-Sheet Breakers for Alzheimers Disease Therapy, Current Drug Targets 2004; 5 (6) . https://dx.doi.org/10.2174/1389450043345290
DOI https://dx.doi.org/10.2174/1389450043345290 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Different Effect of Vitamin D<sub>2</sub> and Vitamin D<sub>3</sub> on Amyloid-β40 Aggregation In Vitro
Current Alzheimer Research Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer’s Disease
Current Alzheimer Research Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology Serotonergic 5-HT2C Receptors as a Potential Therapeutic Target for the Design Antiepileptic Drugs
Current Topics in Medicinal Chemistry Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
Current Pharmaceutical Design Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia
Recent Patents on DNA & Gene Sequences Neuroprotective Actions of Flavones and Flavonols: Mechanisms and Relationship to Flavonoid Structural Features
Central Nervous System Agents in Medicinal Chemistry Recent Developments in Pharmacologic Prophylaxis of Atrial Fibrillation in Patients Undergoing Surgical Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation
CNS & Neurological Disorders - Drug Targets Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Pharmaceutical Design Associations between Periodontitis and Systemic Inflammatory Diseases: Response to Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Interactions Between Apo E and Amyloid Beta and their Relationship to Nutriproteomics and Neurodegeneration
Current Proteomics